A similar reasoning may explain our observation of a trend to worse 10-year survival among ERBB2-amplified node-negative gastric carcinomas, something that was also reported by others in breast carcinomas (Pauletti et al, 2000). The gene discussed is ERBB2; the disease is breast carcinoma.